Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy

Peer Review reports

Original Submission
25 Apr 2022	Submitted	Original manuscript
23 Jun 2022	Reviewed	Reviewer Report - Kirsty Loudon
6 Jul 2022	Author responded	Author comments - Alaa Abouhajar Abouhajar
Resubmission - Version 2
6 Jul 2022	Submitted	Manuscript version 2
Publishing
13 Jul 2022	Editorially accepted
20 Sep 2022	Article published	10.1186/s13063-022-06544-x

Back to article page